Adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD mutation.
- Author:
Guan-guan SU
1
;
Nian-fen ZHAO
;
Yong ZHOU
;
Mei-fang YING
Author Information
- Publication Type:Journal Article
- MeSH: Adenine; adverse effects; analogs & derivatives; therapeutic use; Adult; Aged; Amino Acid Motifs; genetics; Antiviral Agents; therapeutic use; DNA-Directed DNA Polymerase; genetics; Female; Hepatic Encephalopathy; drug therapy; genetics; virology; Hepatitis B virus; genetics; Hepatitis B, Chronic; complications; drug therapy; Humans; Lamivudine; therapeutic use; Liver Cirrhosis; drug therapy; genetics; virology; Male; Middle Aged; Mutation; Organophosphonates; adverse effects; therapeutic use; Protein Structure, Tertiary; genetics; Recurrence; Reverse Transcription; genetics
- From: Journal of Zhejiang University. Medical sciences 2005;34(5):470-472
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of adefovir dipivoxil in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine therapy.
METHODSThe disease relapsed in 14 hepatitis B patients with decompensated liver cirrhosis during lamivudine treatment due to the YMDD motif mutation. All 14 patients had positive HVBDNA and active hepatitis, and were evaluated as Child-Pugh Score C (CPS-C). The patients were treated with lamivudine 50 mg/d and adefovir dipivoxil 10 mg/d for 6 months.
RESULTSOne patient signed off due to non-hypoxemic hyperlactacidemia; other 13 patients showed decreased serum HBVDNA. All patients had serum HBVDNA < or =10(5) copies/ml and 7 patients had HBVDNA < or =10(4) copies/ml. Six patients regained normal serum ALT level and Child-Pugh scores decreased in all patients.
CONCLUSIONAdefovir dipivoxil has satisfied efficacy and safety in treatment of decompensated liver cirrhosis patients with YMDD motif mutation during lamivudine treatment.
